A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment.
about
The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosetsGamma vinyl GABA in the treatment of levodopa-induced dyskinesias in Parkinson's diseaseThe alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's diseaseIdazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's diseaseAlterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPANeuroanatomical phenotyping in the mouse: the dopaminergic system.Chronic thalamic stimulation improves tremor and levodopa induced dyskinesias in Parkinson's diseasePharmacotherapy for advanced Parkinson's disease.Dopamine and GABAA receptor imbalance after ovariectomy in rats: model of menopauseRandomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia.Reliability and validity of a new global dyskinesia rating scale in the MPTP-lesioned non-human primate.Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.Milestones in research on the pathophysiology of Parkinson's diseaseWhat basal ganglia changes underlie the parkinsonian state? The significance of neuronal oscillatory activityAnimal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.Tardive dyskinesia: treatment with aripiprazole.Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's diseaseA tale on animal models of Parkinson's disease.Past, present, and future of the pathophysiological model of the Basal Ganglia.Parkinson's disease: genetics and beyond.Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models.Dopamine-Induced Changes in Gαolf Protein Levels in Striatonigral and Striatopallidal Medium Spiny Neurons Underlie the Genesis of l-DOPA-Induced Dyskinesia in Parkinsonian MiceThe selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan.Metabolic changes following subthalamotomy for advanced Parkinson's disease.Presynaptic modulation of synaptic transmission by opioid receptor in rat subthalamic nucleus in vitro.Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys.Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias.MATTERS ARISING: Inzelberg and Korczyn reply:.Striatal Gαolf/cAMP Signal-Dependent Mechanism to Generate Levodopa-Induced Dyskinesia in Parkinson's Disease.Motor manifestations and basal ganglia output activity: the paradox continues.
P2860
Q28205148-0E9A28F9-B5AF-47CF-B25E-B0F5F77B3E91Q28320193-27937398-FD54-4C26-A8E4-BFB7EC1FCC7BQ28373127-4DB098ED-FC22-45FA-BA6C-36C94CBD28A8Q28375639-0AF42481-F835-4727-B26F-302070669F45Q28376621-052CFB66-70AE-46EF-9E8F-2178530F2C8FQ33227606-102DB348-F6E7-4892-BABC-5B468CCB9C16Q33590695-67EFE160-7189-42B7-9247-6B13E7664AC5Q33821336-034618ED-99D2-41D1-9BCB-84840E06E3A5Q33921621-9DB11F26-91DD-4794-B4B1-CF6938C79854Q34113369-9FCC0B26-CC66-4B1F-ADBB-6917E8DF9C34Q34214529-B01F0169-A3BC-4C36-B31E-AE44C98C48C5Q34325365-D8C7BA6C-74FA-4568-A357-D47AEA76FD0FQ34749047-851BB22F-1CCE-44E5-BB9A-1D32E37F7561Q35053921-F723161A-3316-42E0-AD28-30B42B3F5568Q35589979-D01E02DB-A957-4B87-821B-BB6F79D62F76Q36599203-3A8CBCD6-01E9-4CC5-95EE-CA18BD9C6017Q36947508-E9CCC75B-BBB3-4FA0-9FB7-ED89C91507B0Q37882583-2800F5FC-FE5F-493B-96E7-EB7DE160DC50Q37909948-EF39F6CA-4147-4B48-B998-47D6F72B6208Q39416222-26195188-4F70-4276-882D-F549ABD1130AQ41584434-C2A0B9F5-155F-4B07-A6D4-48E7BA9EB94BQ42322627-FAC5FA82-E991-4450-9C47-F431A729756EQ42486325-BE114910-8519-4C99-968D-1836F84581E8Q43693344-BBFAE50B-B5FE-4236-AB74-96749D9E62EDQ43693346-BD0E8119-AF1E-4BBF-A930-4755A23110F7Q43767019-380848E5-FA8F-4DD6-B142-66ABD4678D38Q43996803-A78F00E9-1119-44F0-B0AA-4459EFDE0B4DQ44165230-7C925033-6E61-4701-BE00-630A74BB794FQ44692125-F3AEA142-0540-4FDC-83DE-5E52354C572AQ44925523-5E0A147D-9A22-4294-83CA-BE8C40E64CE4Q45711922-1DB50DA6-4B60-4869-A2AC-0A509763EBD5Q45867789-1198B270-DF1D-4B12-B360-CD5EC3EF7B20Q47105024-2EF7608A-FC2D-4882-A1FE-CDFA58EF654FQ48125143-D93BABE7-3917-470B-AD5A-96E313951869
P2860
A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 1990
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A hypothesis on the pathophysi ...... uture strategies in treatment.
@en
A hypothesis on the pathophysi ...... uture strategies in treatment.
@nl
type
label
A hypothesis on the pathophysi ...... uture strategies in treatment.
@en
A hypothesis on the pathophysi ...... uture strategies in treatment.
@nl
prefLabel
A hypothesis on the pathophysi ...... uture strategies in treatment.
@en
A hypothesis on the pathophysi ...... uture strategies in treatment.
@nl
P921
P356
P1433
P1476
A hypothesis on the pathophysi ...... uture strategies in treatment.
@en
P2093
Crossman AR
P304
P356
10.1002/MDS.870050203
P407
P577
1990-01-01T00:00:00Z